Neurogene Inc. cash flow to debt ratio of -780.23% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Neurogene Inc.'s free cash flow has decreased 9.73% from $-71.41M last year to $-78.36M, signaling decreasing performance

Neurogene Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Neurogene Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.04 today, signaling strengthened financials

Neurogene Inc. has negative EBITDA, making leverage ratio unreliable

Neurogene Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Neurogene Inc.'s profit margin has increased (-100.00%) in the last year from -8.12K% to 0.00%, signaling increasing performance

Neurogene Inc.'s short-term assets of $271.77M exceed its short-term liabilities of $16.41M

Neurogene Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Neurogene Inc.'s return on equity of -37.88%, is lower than 15.00%, indicating bad performance

Neurogene Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Neurogene Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Neurogene Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Neurogene Inc. has negative free cash flow, indicating cash burn

Neurogene Inc.'s yearly earnings has decreased 20.24% since last year from $-75.14M to $-90.35M, signaling decreasing performance

Neurogene Inc.'s yearly revenue has decreased -100.00% since last year from $925.00K to $0.00, signaling decreasing performance

ROIC -44.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Neurogene Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Neurogene Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Neurogene Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Neurogene Inc. has insufficient data to evaluate this check.

Neurogene Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neurogene Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Neurogene Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Neurogene Inc. has insufficient data to evaluate this check.

Neurogene Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neurogene Inc. has a price-to-book ratio of 3.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Neurogene Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue